PSY67 Longitudinal changes in health-related quality of life for chronic diseases: An example from the hemophilia utilization group study part va (HUGS Va)  by Poon, J.L. et al.
A122 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
OBJECTIVES: The importance of patient-centered outcomes (PCO) in drug 
development is increasingly recognized by health authorities, clinical advisory 
and patient advocacy bodies. Accordingly, many of these organizations seek to 
include PCO in their guidelines and recommendations. However, complex 
disorders present measurement challenges that are difficult to resolve within the 
scope of a clinical trial (CT). An example is Systemic Lupus Erythematosus (SLE), 
characterized by myriad clinical indicator, symptom, severity and frequency 
combinations. SLE patient burden studies demonstrate that, while symptoms 
differ, the impact is universal. This study evaluates the relationship between 
recently updated SLE guidances and concepts reported directly by SLE patients. 
METHODS: A qualitative study comprised of six SLE patient focus groups (N=43) 
was conducted to elicit direct patient input on key symptoms and concepts. FDA 
and EMA guidelines for SLE clinical trials, European League Against Rheumatism 
(EULAR) CT endpoint recommendations, and the Systemic Lupus International 
Collaborating Clinics (SLICC) classification system were evaluated for PCO-
specific content. Patient-reported outcomes (PRO) concepts from the study were 
then compared to the PCO content from the guidelines and recommendations. 
RESULTS: All study subjects (mean age 44.3 years; 91.7% women; 63% diagnosed 
≥ 5 years; 91% experienced flare ≤ 3 months; 74% mild/moderate disease) 
identified fatigue among “most important symptoms” with 98% citing pain and 
44% fog/confusion. Regardless of “importance” all subjects deemed other 
symptoms highly disruptive. EMA and FDA both specify fatigue as a clinical trial 
endpoint. FDA included “fatigue” based on clinician input, but recommended 
development of a PRO-based fatigue exploratory endpoint. EULAR, citing 
challenges of symptom endpoints, suggested general Health-Related Quality of 
Life. The SLICC didn’t mention PCOs. CONCLUSIONS: Patients identified multiple 
SLE symptoms and impacts, yet guidances didn’t address these issues. Joint 
efforts between patients, sponsors, regulators and advisory organizations are 
necessary to implement relevant PCOs, especially in complex disorders.  
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OBJECTIVES: To compare clinical and cost characteristics among patients with 
inflammatory bowel disease (IBD) receiving biologic medication in an in-office 
setting (IOI), hospital outpatient department (HOPD), or ambulatory clinic. 
METHODS: A syndicated study of IBD patients was conducted. Patients aged ≥18 
years were recruited via the National Health and Wellness Survey and 
Lightspeed Research Panel to complete a survey during August–November 2010. 
Patients were asked about health care utilization, concomitant medications, IBD 
symptoms, quality of life (QoL) and out-of-pocket (OOP) costs. To measure 
utilization, the number of provider, emergency room (ER), and hospital visits in 
the past 6 months was collected. The Medical Outcomes Study (MOS) IBD 
questionnaire was used to assess QoL. Bivariate differences were assessed using 
Fisher’s exact tests for categorical variables and ANOVAs for continuous 
variables. RESULTS: Of 175 IBD patients, 54% (n=94) received biologic medication 
in an IOI setting, 35% (n=61) in an HOPD setting, and 11% (n=20) in an ambulatory 
clinic. The number of ER and hospital visits were similar across groups, however 
IOI patients had greater provider visits (p<0.05). Though concomitant medication 
utilization was generally similar, significantly more IOI patients received steroids 
compared to HOPD patients (p<0.05). Most IBD symptoms did not differ across 
groups. However, HOPD patients were more likely to have fistulas than IOI 
patients (30% vs. 16%; p<0.05), and IOI patients were less likely to experience 
bowel movements than HOPD or clinic patients (55% vs. 84% and 80%, 
respectively). HOPD patients had lower OOP costs for biologic medications and 
higher QoL scores compared to IOI patients (p<0.05). CONCLUSIONS: Among IBD 
patients receiving biologic medication in an IOI, HOPD, or ambulatory clinic 
setting, HOPD patients had higher QoL and lower OOP costs, however, few other 
differences were identified. Further research is needed to elucidate these 
findings.  
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CORRELATES OF IMPROVEMENT IN PHYSICAL QUALITY OF LIFE AND QUALITY 
OF SLEEP AMONG CHRONIC LOW BACK PAIN PATIENTS WITH TREATMENT 
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OBJECTIVES: Deficits in physical health-related quality of life (HRQL) and sleep 
quality in chronic low back pain (CLBP) patients may be alleviated with 
Buprenorphine Transdermal System (BTDS) treatment. This post-hoc analysis of 
clinical trial data aimed to explore whether BTDS treatment has a direct impact 
on HRQL and sleep quality, an indirect impact on the outcomes as mediated 
through its impact of pain, or both; and to identify significant correlates of HRQL 
and sleep quality. METHODS: In this multicenter, enriched, double-blind, 
randomized trial, opioid-naïve patients with moderate-to-severe CLBP received 
twelve weeks’ treatment with BTDS (10 or 20 mcg/hour) or placebo. A series of 
multivariate linear regression models (stepwise) predicting physical HRQL, sleep 
disturbance, and sleep quality at week 12 were fitted. Physical HRQL was 
measured using the SF-36v2 Physical Component Summary (PCS), while sleep 
outcomes were measured using the Disturbance subscale and Sleep Problems 
Index (SPI) of the Medical Outcomes Study Sleep Scale (MOS-SS). For each 
outcome, models 1 and 2 included baseline demographic and clinical variables, 
model 3 added treatment arm, and model 4 added pain assessment at week 8. 
RESULTS: Results from model 3 supported BTDS treatment as a significant 
predictor of better physical HRQL and sleep outcomes. Model 4 results for each 
outcome indicated that pain was a partial mediator of treatment on physical 
HRQL and sleep quality, meaning that treatment had both direct and indirect 
effects on these outcomes. Mid-trial pain and the baseline value of the outcome 
being tested (i.e., PCS score, Disturbance score, or SPI score) were the strongest 
predictors for each outcome. CONCLUSIONS: For CLBP patients, improvements 
in physical HRQL, sleep disturbance, and sleep quality were impacted by BTDS 
treatment both directly as well as indirectly via mediation through the 
treatment-driven reductions in pain. Mid-trial pain strongly predicted to HRQL 
and sleep outcomes.  
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RESPONSIVENESS AMONG PATIENT-REPORTED MEASURES OF QUALITY OF 
LIFE, QUALITY OF SLEEP, AND FUNCTIONAL DISABILITY TO PAIN AND IMPACT 
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LOW BACK PAIN PATIENTS  
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1Optum, Lincoln, RI, USA, 2Purdue Pharma L.P., Stamford, CT, USA  
OBJECTIVES: Patients with moderate-to-severe chronic low back pain (CLBP) who 
are treated with Buprenorphine Transdermal System (BTDS) experience 
improvements in three patient-reported outcomes: quality of life (QoL), sleep 
quality, and functioning. This analysis compared the relative responsiveness of 
measures of each outcome to treatment and treatment-driven changes in pain. 
METHODS: This post-hoc analysis used data from an enriched, 12-week double-
blind, randomized placebo-controlled trial evaluating BTDS (10 or 20 mcg/hour) 
for treatment of pain in opioid-naive patients with moderate-to-severe CLBP. 
The trial repeatedly assessed QoL (SF-36v2), sleep quality and problems (Medical 
Outcomes Study Sleep Scale [MOS-SS]), and functional disability (Oswestry 
Disability Index [ODI]) in addition to measures of pain. Responsiveness of each 
instrument to treatment and changes in pain were examined using analysis of 
covariance, t-tests, and effect sizes for comparison of effects of time, treatment, 
and magnitude of pain reduction. The interrelation among PROs was also 
examined. RESULTS: The SF-36v2 and ODI showed better responsiveness to 
treatment and changes in pain than did the MOS-SS. Among subscales of the 
MOS-SS, only Disturbance showed substantial correlations with other PRO and 
pain measures and substantial differences across time, treatment, and pain 
reduction status groups. Several of the QoL domains measured by the SF-36v2, 
particularly Bodily Pain, Physical Functioning, Role Physical, Social Functioning, 
and Vitality, showed considerable responsiveness to treatment and pain. For the 
ODI, the Pain Intensity subscale showed the greatest responsiveness, with the 
majority of the remaining subscales showing more moderate, but still 
meaningful, levels of responsiveness. PRO measures were, in general, 
moderately inter-correlated, particularly between SF-36v2 and ODI subscales. 
CONCLUSIONS: Pain subscales on the SF-36v2 and ODI showed the greatest 
responsiveness to treatment. Substantial responsiveness was also observed for 
the majority of QoL and functioning domains, as well as sleep disturbance. 
Subscales of PRO instruments were generally moderately inter-correlated.  
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OBJECTIVES: Obesity has become a major public health problem worldwide. In 
Singapore, the prevalence of obesity among adults aged 18-69 years increased 
from 6.9% in 2004 to 10.8% in 2010. To the best of our knowledge, no single 
obesity-specific HRQoL instrument comprehensively covered areas of life that 
are important to obese individuals. Therefore we sought to assess the content 
validity of FABQOL, a newly developed instrument, to address the gap. 
METHODS: FABQOL (76 items) was developed based on literature review and 
mapped to obesity-specific International Classification of Functions Disability 
and Health (ICF) categories. Content validity (i.e. item comprehension and 
content coverage) was assessed through individual cognitive debriefing 
interviews with 30 English-speaking, ethnic Chinese, Malay and Indian 
overweight/obese patients from a weight management clinic at a public hospital 
in Singapore. For each item, we asked participants if the item was important to 
them (yes/no). Items that were perceived as not important by at least 50% of the 
participants and items that were not understood by at least 20% of the 
participants were removed. Participants were also asked to suggest additional 
items that were important. RESULTS: Participants aged from 23-58 years (median 
age = 45), one-third were men and 90% were obese (BMI>27.5kg/m2). Two items 
“being able to eat as much as I want to” and “being able to reach for objects 
placed above me” were perceived as not important by 26 (87%) and 15 (50%) of 
participants respectively. Four items (“lethargic”, “distressed”, “anxious” and 
“stigmatized”) were removed because they were poorly understood. Three 
participants suggested three new items pertaining to relationship with close 
friends, company image and personal leisure activities. CONCLUSIONS: The 
revised FABQOL comprises 73 items that were generally easy to understand and 
important to overweight/obese patients in Singapore. Psychometric properties of 
FABQOL will be evaluated in a larger study.  
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OBJECTIVES: In chronic diseases, health-related quality of life (HRQoL), a key 
health outcome measure, varies not just between- but also within-individual 
patients over time due to acute changes in clinical or environmental 
circumstances. Cross-sectional assessments of HRQoL consider only between-
patient differences and do not reflect within-patient changes, which require 
multiple assessments over time. This study aims to disaggregate the between- 
and within-individual factors influencing HRQoL over time in persons with 
hemophilia A. METHODS: In a two-year observational prospective study of 
health care utilization and burden of illness in US hemophilia A patients (HUGS 
Va), the SF-12 (adults) and PedsQL (children aged <18 years) was used to assess 
HRQoL at baseline, 6, 12, 18 and 24 months. Information was also collected about 
disease severity, sociodemographic variables, annual bleeding and emergency 
room visits frequencies and missed days from work/school. RESULTS: Only small 
variations in HRQoL were observed over time in the entire study population of 
157 adults and 164 children, of which 64.6% have severe disease. At baseline, 6, 
12, 18 and 24 months, adult mean mental component scores were 50.9±10.1, 
49.8±9.7, 50.2±10.2, 49.5±10.6 and 50.4±9.5 respectively, while mean physical 
component scores were 43.4±10.7, 43.3±10.8, 50.2±10.2, 49.5±10.6 and 50.4±9.5 
respectively. Among children, mean psychosocial functioning scores at each 
follow-up were 84.1±15.3, 83.3±13.3, 80.3±15.6, 83.5±16.0 and 82.9±13.2 
respectively, while mean physical functioning scores were 89.5±15.2, 85.5±17.8, 
82.7±22.3, 85.7±18.0 and 84.7±17.3 respectively. After plotting the HRQoL scores of 
individuals over time, however, greater variations in the magnitude and pattern 
of fluctuation can be observed, reflecting acute within-patient changes. 
CONCLUSIONS: HRQoL fluctuates over time on the individual level, but not at 
the study population level as aggregation of scores to the mean masks individual 
variation. In order to identify factors influencing changes in HRQoL across time, 
multivariate multilevel modelling will be employed to disaggregate between- and 
within-individual differences in HRQoL.  
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HEALTH-RELATED QUALITY OF LIFE IN A PORTUGUESE COHORT OF PATIENTS 
WITH SYSTEMIC LUPUS ERYTHEMATOSUS  
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OBJECTIVES: To analyse the impact of systemic lupus erythematosus (SLE) on 
Portuguese patients’ quality of life. METHODS: Study conducted in one 
Portuguese hospital with a Auto-immune Disease Unit, sample size were 116 
patients with SLE. All patients fulfilled the American College of Rheumatology 
(ACR) 1997 revised criteria for the classification of SLE and the date at which the 
fourth SLE classification criterion was observed was recorded as the date of 
diagnosis. Patients were grouped into 3 distinct phenotypes namely neuro-
psychiatric (NPSLE), nephritis and non-NPSLE non-nephritis sub-groups. Quality 
of life measured through SF-36 and EQ-5D. Questionnaires were sent by mail and 
participation was voluntary and confidential. RESULTS: Sixty eight per cent valid 
answers were received (n=79). Respondents were predominantly female (89%) 
with average age 45 years. In these, the average length of disease was 12.3 (±8.7) 
years. Average ACR criteria was 5.1 (±1.26) Quality of life measured through EQ-
5D was 0.61 (±0,32) with a large majority of answers between 0,5 and 1,0. The 
average value for SF-36 mental component was 65 and the physical component 
was 66. CONCLUSIONS: Age was negatively correlated at a significant level with 
results obtained for EQ-5D and the physical component of SF-36. Disease 
duration was also negatively correlated at a significant level with the physical 
component of SF-36. Correlation between QoL instruments was found to be in 
accordance with studies in other countries. QoL measured through SF-36 was 
consistently lower than the Portuguese norm. Results of QoL in Portuguese 
patients with SLE found to be comparable to the scarce available evidence in 
other countries. For both instruments Portuguese patients with SLE reported 
worst HRQoL than Portuguese patients with psoriasis.  
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OBJECTIVES: To characterize physician practice patterns and their approaches 
towards assessment and management of SLE patients in usual practice settings 
in the United States. METHODS: Actively practicing rheumatologists with >= 3 
years of treating SLE were recruited from a panel of > 4,000 rheumatologists in 
the U.S. Physicians completed an online survey covering SLE practice patterns, 
viewpoints and patient communication approaches. Descriptive analyses were 
conducted on the overall sample; subgroups were compared using chi-square 
and t-tests, as appropriate. RESULTS: Between February and April 2012, 304 
physicians from 42 states completed the survey [68% male; mean age: 49; 69% 
community/non-academic; 69% Caucasian)]. Physicians treated SLE patients for a 
mean of 16 years. Mean(SD) time spent by physicians with patients was 52(15) 
minutes at initial visit and 22(7) minutes at follow-up visits. Overall distribution 
of SLE disease severity was 46% mild, 37% moderate, and 17% severe. 73% of 
patients had adequately controlled SLE; and 20% were on moderate to high dose 
of steroids. While 64% of physicians reported involving patients in treatment 
decisions ‘often/very often’, physicians were evenly divided (52% vs. 48%) in 
whether doing so does or does not ‘improve outcomes a lot’. A greater proportion 
of physicians in the former group believed that (a) patient knowledge of clinical 
tests helped improve adherence (51% vs. 32%; p=0.001); b) SLE has a very high 
impact on patient quality of life (27% vs. 17%; p=0.002); c) had greater satisfaction 
with patient interactions (8 vs. 8.4; scale 0-10; p=0.007); and reported setting 
goals with their patients (78% vs. 68%; p=0.05). CONCLUSIONS: Approximately 
half of surveyed physicians believe that involving patients in treatment plans is 
important to attaining favorable outcomes. This belief corresponds to a greater 
appreciation of doctor-patient interactions. Its impact on SLE outcomes and 
factors influencing this belief warrant further research.  
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APPROACHES TO PAIN MANAGEMENT AMONG OLDER AND YOUNGER ADULTS 
EXPERIENCING MODERATE TO SEVERE PAIN IN A NATIONAL HEALTH SURVEY: 
TOO MUCH OR NOT ENOUGH?  
Vo L1, Annunziata K2, Lapane K3 
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OBJECTIVES: To describe pain management among older adults reporting 
moderate to severe pain and to evaluate the extent to which polypharmacy in 
pain management is associated with greater medication side effects. METHODS: 
The 2011 US National Health and Wellness Survey was used. Participants 
completed a self-administered, internet-based questionnaire, reported pain 
medications (e.g. specific medication, duration of use, days used in past month) 
grouped by number of prescriptions used (0, 1, ≥ 2) and the World Health 
Organization Pain Ladder guidelines. Participants were at least 65 years of age. 
Analyses were appropriately weighted for the complex survey design. RESULTS: 
Of the 16,500 participants ≥65 years of age, 35.9% reported pain in the past 12 
months, with 66% reporting moderate/severe pain. The most common sources of 
pain were: arthritis pain (66.1%), back problems (58.5%), and joint pain (55.3%). 
Daily pain was reported in 60%. Among older adults experiencing 
moderate/severe pain, 50% received no prescription pain medication, 32% 
received one prescription, and 18% received ≥ 2 prescriptions for pain. Relative to 
one prescription, those reporting ≥ 2 prescriptions received stronger analgesics 
(WHO level 3: 28.3% vs. 8.2% for ≥ 2 vs. 1; WHO Level 2: 55.0% vs. 45.2% for ≥ 2 vs. 
1). Use of adjuvants to pain medications were more common in those with ≥ 2 
relative to 1 pain medication. Compared to participants on 1 prescription pain 
medication reporting at least one side effect (n=194), participants on ≥ 2 pain 
medications reporting at least one side effect (n=197) were significantly more 
likely to report bloating (11.0% vs. 6.8%), nausea (16.5% vs. 5.1%), trouble thinking 
clearly (19.0% vs. 6.7%), and sleepiness (47.5% vs. 25.6%). CONCLUSIONS: 
Moderate/severe pain is common among older adults, and for most, occurs daily. 
Pain management appears to be suboptimal and may include polypharmacy in 
pain management as well as under-treatment of pain.  
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GAINING A PRODUCT ORPHAN DESIGNATION IS NOT INDICATIVE OF 
IMPROVED MARKET ACCESS SUCCESS IN EUROPEAN COUNTRIES  
Gisby M1, Bache G1, Paglia B2, Patel V1 
1PAREXEL Consulting, Uxbridge, UK, 2PAREXEL Consulting, Billerica, MA, USA  
OBJECTIVES: Within the EU, pharmaceutical products in development may 
apply for an orphan product designation if the product can demonstrate 
potential value in a rare disease indication. Not all products used in rare diseases 
apply for or receive such a designation. The research question posed was 
whether gaining an orphan drug designation in the EU is indicative of a rare 
disease product achieving greater market access success. METHODS: Products 
receiving an EU Marketing Authorisation (MA) between 2009-2011 with an 
orphan designation were compared with those that were approved for at least 
one indication of use in a rare disease. Indicative markers of market access 
success were reviewed, including outputs of product evaluation 
recommendations from the Scottish Medicines Consortium and HAS in France. 
Additionally, 16 payers in 4 European countries were interviewed for qualitative 
insights on how an orphan designation would impact on their evaluation of 
price. RESULTS: Fourteen (14) products with orphan-product designation 
received an EU MA during 2009-2011. Twenty (20) products without orphan-
designation but with at least one indication for a rare disease received an EU MA 
during 2009-2011. Forty two (42)% of the orphan designated products gaining an 
EU MA received a recommendation for use in Scotland, with 67% of non-orphan 
designated products indicated for a rare disease receiving a recommendation for 
use. Ninety two (92)% of the orphan designated products were included on the 
reimbursement list in France, with 89% of non-orphan designated products 
included on the reimbursement list. Payers indicated that orphan drug status is 
methodologically difficult to consider in relation to price, but it may have other 
relevant market access benefits. CONCLUSIONS: For products with an MA for 
treating rare diseases, the analysis performed concluded that products receiving 
an EU orphan drug designation did not demonstrate greater market access 
success in the selected EU countries using the applied criteria.  
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OBJECTIVES: In the European Union (EU), rare diseases are defined as life-
threatening or chronically debilitating diseases with prevalence lower than five 
